<DOC>
	<DOCNO>NCT01678677</DOCNO>
	<brief_summary>The purpose study assess safety , reactogenicity immunogenicity 8 different formulation investigational NTHI vaccine current former smoker , 50-70 year age .</brief_summary>
	<brief_title>A Study Evaluate Safety , Reactogenicity Immunogenicity GSK Biologicals ' Non-typeable Haemophilus Influenzae ( NTHi ) Investigational Vaccine ( GSK2838497A ) Current Former Smokers</brief_title>
	<detailed_description>This Protocol Posting update follow Protocol Amendment 1 , date 10 October 2012 , lead change inclusion criterion .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Respiration Disorders</mesh_term>
	<mesh_term>Respiratory Tract Diseases</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects , opinion investigator , comply requirement protocol . A male female , include , 50 70 year age time first vaccination . Written inform consent obtain subject . Subjects without medical history , clinical find laboratory find opinion investigator could pose safety concern interfere protocol . Current former smoker . A smoke history least 10 packyears . Female subject nonchildbearing potential may enrol study . Female subject childbearing potential may enrol study , subject : practiced adequate contraception 30 day prior vaccination , negative pregnancy test day vaccination , agree continue adequate contraception entire treatment period 2 month completion vaccination series . Use investigational nonregistered product study vaccine within 30 day precede first dose study vaccine , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational vaccine/product . Planned administration/ administration vaccine foreseen study protocol period start 30 day first dose end 30 day last dose vaccine , exception influenza vaccine may administer â‰¥ 15 day precede follow study vaccine dose . Previous vaccination vaccine contain NTHiantigens . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Topical steroid allow . Administration immunoglobulins and/or blood product within 3 month precede first dose study vaccine plan administration study period . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination . History current autoimmune disease . Postbronchodilator Forced Expiratory Volume 1 second ( FEV1 ) &lt; 80 % predict normal value . Diagnosed respiratory disorder . Please note subject mild pulmonary obstruction enrol . Laboratory evidence clinically significant haematological abnormality Screening . Acute disease and/or fever time enrolment . Current alcoholism and/or drug abuse . Has significant disease , opinion investigator , likely interfere study and/or likely cause death within study duration . History current condition prevent intramuscular injection bleed coagulation disorder . Has contraindication spirometry test . Malignancies within previous 5 year lymphoproliferative disorder . Pregnant lactate female . Female plan become pregnant planning discontinue contraceptive precaution . Any condition investigator judge may interfere study finding .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>non-typeable Haemophilus influenzae</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>reactogenicity</keyword>
	<keyword>safety</keyword>
</DOC>